Invezz

Looking to diversify away from AI trade? Buy these 3 stocks

Looking to diversify away from AI trade? Buy these 3 stocks
Wajeeh Khan
17 July 2026, 22:58 PM

powered by

Invezz
Buy LLY

Buy Eli Lilly (LLY). The news highlights GLP-1 dominance (Mounjaro/Zepbound) driving 56% YoY revenue growth and a major EPS jump, plus raised full-year sales guidance—this is quality growth with pricing power, not a cyclical AI proxy. In a rotation out of AI, LLY should hold up better because demand is tied to chronic disease and the market is still expanding.

Key Risk: Regulators or competitors materially cut GLP-1 pricing/market share (or supply constraints ease demand), breaking the growth-and-pricing-power moat.

Buy MCD

Buy McDonald’s (MCD). The article frames it as recession-resistant: strong top-line momentum, positive worldwide comps, and margin expansion with value campaigns gaining share. In an AI-volatility unwind, MCD is a cash-flow anchor that can keep comp sales steady while the market de-rates riskier growth.

Key Risk: A sustained consumer slowdown forces deeper discounting, compressing margins and reversing the share-gain story.

  • UBS has named several non-AI stocks worth owning for 2026.
  • It's particularly bullish on Eli Lilly, McDonald's, and Charles Schwab.
  • Here's what LLY, MCD, and SCHW have in store for investors this year.

For investors seeking to pare exposure to the artificial intelligence (AI) trade amid boom-induced volatility, shifting capital toward overlooked equities offers a compelling strategic alternative.

Market participants are increasingly adopting a “defensive posture” against a possible downturn – pivoting to segments where high-quality operators with solid fundamentals have fallen out of favor leading to unwarranted valuation de-ratings.

UBS recently highlighted a rotation into quality defensive and value sectors as a robust method to diversify.

While AI infrastructure and semiconductor indices experience massive corrections in 2026 – other sectors present lucrative, risk-adjusted sanctuaries.

Here are three powerhouse stocks offering robust fundamentals and substantial upside as earnings season approaches.

Eli Lilly (LLY)

Eli Lilly stock stands as a secular growth juggernaut insulated from tech cyclicality.

The bullish narrative is anchored by the company’s absolute dominance in the GLP-1 weight-loss and diabetes market, acting as a profound defensive moat against macroeconomic shocks.

During Q1, the pharma giant reported worldwide revenue of USD 19.8 billion (approx. $28.9 billion), a staggering 56% year-over-year growth.

This surge was primarily driven by Mounjaro and Zepbound – which generated a combined USD 12.8 billion (approx. $18.7 billion).

Mounjaro revenue alone jumped 125% year-over-year, helping company-wide non-GAAP earnings per share (EPS) to come in at $8.55 – up a whopping 156%.

Management recently raised its full-year sales guidance by USD 2 billion (approx. $2.9 billion), projecting up to USD 85 billion (approx. $123.9 billion).

This explosive acceleration and unparalleled pricing power make it a premier non-tech asset.

McDonald’s (MCD)

McDonald’s represents the quintessential defensive equity – capturing institutional capital rotating into traditional value sectors.

The primary driver is its proven ability to command pricing power and maintain consumer volume regardless of the broader economic climate.

In Q1, the fast-food titan delivered its strongest top-line performance in eight quarters – with total revenue hitting USD 6.5 billion (approx. $9.5 billion), a 9.4% increase on a year-over-year basis.

Worldwide comparable sales grew 3.8% across all operating segments, supported by targeted value campaigns that consistently outpace competitors in gaining market share.

Operating margins expanded materially to 45.3%, pushing adjusted EPS up to $2.83.

For investors building a protective portfolio shield, MCD offers “recession-resistant” fundamentals that reliably weather systemic market froth.

Charles Schwab (SCHW)

Rounding out the diversification strategy is Charles Schwab – a financial sector standout providing an excellent hedge against tech exposure.

The bullish thesis relies on accelerating net interest revenues, massive asset-gathering capabilities, and stabilizing funding costs.

Financials for early 2026 demonstrate immense operational momentum.

Q1 sales climbed to USD 6.5 billion (approx. $9.4 billion), reflecting a 15.7% year-over-year increase.

SCHW is cutting reliance on higher-cost bank supplemental funding while “attracting billions” in core net new assets and expanding active brokerage accounts.

With forward projections pointing toward a 16% year-on-year rise in net interest revenue, Schwab capitalizes effectively on a stabilizing rate environment.

A 1.25% dividend yield makes SCHW shares even more attractive to own in 2026.